Bcl-2 family proteins are highly conserved molecules that play a crucial role in regulating the release of apoptotic proteins from mitochondria. They possess Bcl-2 homology (BH) domains, which are ...
Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma ...
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic ...
BUFFALO, NY- September 1, 2022 – A new research paper was published in Aging ("Aging (Albany NY)" by Medline/PubMed, "Aging-US" by Web of Science) on the cover of Volume 14, Issue 16, entitled, ...
China’s National Medical Products Administration approved Ascentage Pharma Group Corp. Ltd.’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) for treating adults with chronic lymphocytic ...
A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows ...
While Eli Lilly celebrated a “solid quarter” of earnings this morning, a look over the Big Pharma’s third-quarter presentation reveals that the company has quietly dumped two clinical-stage assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results